Journal of Pharmacology and Experimental Therapeutics
June 1, 1988
Jr Jf Nash, Herbert Y. Meltzer, Gary A. Gudelsky
The racemic mixture of 3,4-methylenedioxymethamphetamine (MDMA), which has been reported to produce selective destruction of serotonergic neurons in the central nervous system, was studied to determine its neuroendocrine and temperature effects and mechanism of action. MDMA elevated serum concentrations of corticosterone in doses ranging from 3 to 20 mg/kg administered i.p. Serum corticosterone...
Clinical Chemistry
May 1, 1988
José Manuel Ramos, Robert L. Fitzgerald, Alphonse Poklis
10 citations
Journal Article MDMA and MDA cross reactivity observed with Abbott TDx amphetamine/methamphetamine reagents. Get access J M Ramos, Jr, J M Ramos, Jr Dept. of Pathol., Med. College of Virginia, Virginia Commonwealth University, Richmond 23298 Search for other works by this author on: Oxford Academic Google Scholar R L Fitzgerald, R L Fitzgerald Dept. of Pathol., Med. College of Virginia,...
Brain Research
April 12, 1988
George A. Ricaurte, L. Delanney, I. Irwin et al.
This study compared the toxic effects of oral versus subcutaneous and single versus multiple doses of 3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in non-human primates. Orally administered MDMA was approximately one-half as effective as subcutaneously administered drug. Multiple doses were more effective than single doses, but a single 5 mg/kg dose of MDMA given...
JAMA
March 18, 1988
Jamyl Alrazi
91 citations
To the Editor. —Drs Brown and Osterloh,1in a recent letter inTHE JOURNAL, reported a nearly fatal toxic reaction to 3,4-methylenedioxymethamphetamine (MDMA). The estimated dose of MDMA administered was 100 to 150 mg and the blood levels, measured at one and two hours after hospital admission, were 6500 and 7000 ng/mL, respectively. Before MDMA became a Schedule 1 drug on July 1, 1985,2it was...
Journal of Pharmacology and Experimental Therapeutics
March 1, 1988
Michel Johnson, A. Letter, Kalpana M. Merchant et al.
This study demonstrates that the isomers of 3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxymethamphetamine (MDMA) are different in their ability to induce changes in serotonergic parameters and nigral concentrations of neurotensin-like immunoreactivity. With five successive doses (3.5 mg/kg) the d-MDA isomer was more potent than the l-MDA in its ability to decrease the concentrations...
Pharmacology, Biochemistry, and Behavior
March 1988
L H Gold, G F Koob
Although some substituted amphetamines, like MDA, produce a combination of sympathomimetic stimulation and perceptual alterations, the psychoactive qualities of MDMA are less distinctive. MDMA binds to serotonergic receptors and has been shown to potently deplete brain serotonin concentrations. Biochemical and behavioral evidence suggests that MDMA may also act on the dopamine system. The...
Psychopharmacology
1988
Robert Oberlender, D E Nichols
The term entactogen has recently been introduced to describe a new pharmacological class of compounds best represented by 3,4-methylenedioxymethamphetamine, MDMA, and its alpha-ethyl homologue MBDB. The present study was designed to test the similarities of the discriminative stimulus properties produced by MDMA and MBDB, as well as to elaborate further the distinction between entactogens,...
Psychopharmacology
1988
C B Hubner, M Bird, S Rassnick et al.
3,4-Methylenedioxymethamphetamine (MDMA) is a psychoactive phenylisopropylamine which is structurally similar to both amphetamine-related sympathomimetics and the hallucinogen, mescaline. MDMA produces pleasurable effects which include euphoria, and recent reports continue to demonstrate its widespread recreational use. The aim of the present study was to assess the effects of racemic MDMA on...
Neuropharmacology
December 1987
Donna M. Stone, Kalpana M. Merchant, Glen R. Hanson et al.
In the rat, administration of the psychoactive analog of amphetamine 3,4-methylenedioxymethamphetamine (MDMA), causes selective, pronounced decreases in markers of central serotonergic function. The time course of these neurochemical changes was examined in several serotonergic nerve terminal regions of the brain. Fifteen min after subcutaneous injection of MDMA (10 mg/kg), the enzymatic...
The International Journal of Psychiatry in Medicine
December 1, 1987
Robert P. Climko, Herbert Roehrich, Donald R. Sweeney et al.
77 citations
The Drug Enforcement Administration classified the drug methylenedioxymeth-amphetamine, MDMA, also known as Ecstacy, as a Schedule I controlled substance on July 1, 1985. The controversy surrounding the classification of MDMA is related to the question of its efficacy as an adjunct to psychotherapy and the larger issue of how to regulate the production and use of designer drugs. The authors...